foxo4-dri peptide senolytic 2023 study

foxo4-dri peptide senolytic 2023 study Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Targeted Apoptosis of Senescent Cells

Name: foxo4-dri peptide senolytic 2023 study Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Targeted Apoptosis of Senescent Cells
Brand: iglepidom.org
SKU: 5140542253
Price: 24.83 USD
Availability: InStock
Rating: 4.6012 (12 reviews)

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine foxo4 dri peptide senolytic 2023 study Molecular modelling of the FOXO4 TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4 DRI induces keloid senescent fibroblast FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC

SKU: 5140542253 · From iglepidom.org

4.6

USD24.83 USD62.83

Pay in 4 interest-free payments of $6.21 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

Peptide therapy is one of the fastest-growing areas of functional and longevity medicine

10.3390/ph16060899 270 SmithB

A., Menezes, J

Cell Stem Cell 5: 320331 Li L, Candelario KM, Thomas K, Wang R, Wright K, Messier A, Cunningham LA (2014) Hypoxia inducible factor1alpha (HIF1alpha) is required for neural stem cell maintenance and vascular stability in the adult mouse SVZ